Clinical Validation on Healthy Humans of a Portable Non-Invasive Continuous Glucose Monitor Based on Transdermal Band-Pass Raman Spectroscopy
Authors' conclusion
These results demonstrate that the BPR-CGM technology can achieve clinical-grade accuracy comparable to invasive systems
Study context
- Population
- Healthy humans undergoing a standard OGTT
- Participants
- 6 participants
- Comparison
- Non-invasive BPR-CGM vs standard blood glucometer and two commercial needle-based continuous glucose monitoring (CGMs)
- Outcome
- Mean absolute relative difference vs reference blood glucose during standard OGTT
Methodological detailsnon-invasive, oral glucose tolerance test
- Non-invasive
- Oral glucose tolerance test
Performance
As reported in the abstract
Further findings
Parkes (consensus) error grid
- All BPR-CGM readings within clinically acceptable zones A and B
Glucose trends
- BPR-CGM trends closely matched reference blood glucose without algorithmic lag compensation
Safety
Adverse skin reactions · following the trial
- No adverse skin reactions observed
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Clinical Validation on Healthy Humans of a Portable Non-Invasive Continuous Glucose Monitor Based on Transdermal Band-Pass Raman Spectroscopy. J Diabetes Sci Technol. Published 30 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →